| Previous Close | 4.25 |
| Open | 4.16 |
| Bid | 4.31 x 1200 |
| Ask | 7.21 x 800 |
| Day's Range | 4.16 - 4.40 |
| 52 Week Range | 3.61 - 8.55 |
| Volume | 19,212 |
| Avg. Volume | 66,319 |
| Market Cap | 72.481M |
| Beta | 0.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.87 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CALGARY, Alberta and SAN DIEGO, Aug. 03, 2018-- Oncolytics Biotech ® Inc., currently developing REOLYSIN ®, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced financial ...
CALGARY, Alberta and SAN DIEGO, July 31, 2018-- Oncolytics Biotech ® Inc., currently developing REOLYSIN ®, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that ...
Over the last week or so, Oncolytics (ONCY) (ONC.TO) has experienced a flurry of activity from announcing a research collaboration with the Keck School of Medicine, to raising additional cash in preparation for their Phase III trial. Oncolytics also presented at the ASCO conference discussing a poster highlighting biomarkers that are predictive of response by checkpoint inhibitors. Since our update on the quarter, Oncolytics forged a collaboration with the Keck School of Medicine at USC to examine the use of their lead candidate pelareorep in combination with Keytruda, Velcade and dexamethasone for multiple myeloma.
Oncolytics Biotech® Inc. (ONC.TO) (ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the closing of its previously announced underwritten public offering of 1,532,278 common shares, including 160,065 common shares pursuant to the exercise of the underwriters’ option to purchase additional common shares (the “Offering”). The gross offering proceeds to the Company from this Offering are approximately USD $8.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Offering was made pursuant to a U.S. registration statement on Form F-10, declared effective by the United States Securities and Exchange Commission (the “SEC”) on May 7, 2018 (the “Registration Statement”), and the Company’s existing Canadian short form base shelf prospectus (the “Base Shelf Prospectus”) dated May 4, 2018.
CALGARY, Alberta and SAN DIEGO, June 04, 2018-- Oncolytics Biotech ® Inc., currently developing REOLYSIN ®, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a ...
CALGARY, Alberta and SAN DIEGO, June 01, 2018-- Oncolytics Biotech ® Inc., currently developing REOLYSIN ®, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that ...